## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 1 of 55

#### **ADMITTED TRIAL EXHIBITS**

Exhibit	Description	Date Admitted	Witness(es)
1512	Jan-Feb 2014 Email String re SOPs for EDISON Total T4, Total T3, Testosterone, FSH	03/22/2022	Erika Cheung*
1557	2014-02-22 Pandori Email to Cheung re Task Assignments	03/22/2022	Erika Cheung*
1562	Apr. 10-11, 2014 Email String re Follow up to previous discussion	03/22/2022	Erika Cheung*
1587	Feb. 2014 Email String re 3.5 Readers	03/22/2022	Erika Cheung*
1633	2014-03-28 Email String re Failed QC	03/22/2022	Erika Cheung* Dr. Adam Rosendorf
3741A	Theranos Testing Menu	03/22/2022	Erika Cheung* Nimesh Jhaveri Lisa Peterson
5387Н	2011-2016 Misc. Text Messages	03/22/2022	Erika Cheung* So Han Spivey Nimesh Jhaveri Dr. Sunil Dhawan Sarah Bennett Daniel Mosley Brian Grossman
5388	Photo of Edison Machine	03/22/2022	Erika Cheung*
5389	Photo of Siemens ADVIA	03/22/2022	Erika Cheung*
9368	Theranos TSH ELISA Assay Report – Validation Document; TSH – ELISA Assay Validation Report on Edison 3.X Theranos System [Revision A]	03/22/2022	Erika Cheung*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 2 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
9909	Theranos Quality Operating Procedure – CLIA Laboratory; Corrective and Preventative Action [2011-06-09]	03/22/2022	Erika Cheung*
9925	Theranos Standard Operating Procedure – CLIA Laboratory: Total 25-OH Vitamin D on Edison 3.5 Theranos System	03/22/2022	Erika Cheung*
10224	Resume of Sharada Sivaraman, Ph.D.	03/22/2022	Erika Cheung*
20020	2013-09-14 Theranos Employment Offer Letter to Erika Cheung	03/22/2022	Erika Cheung*
20029	201-10-14 Theranos At-Will Employment, Confidential Information and Invention Assignment Agreement	03/22/2022	Erika Cheung*
20043	2013-12-16 Email String re Reassignment to CLIA	03/22/2022	Erika Cheung*
1227	Nov. 2013 Email String re New Daily Demo Schedule	03/23/2022	Erika Cheung*
1287	Nov. 2013 Email String re QC Controls for Vit. D	03/23/2022	Erika Cheung*
1323	Dec. 2013 Email String re QCs failing with updated Range	03/23/2022	Erika Cheung*
1431	Jan. 2014 Email String re QC for EDISONS	03/23/2022	Erika Cheung*
1589	Feb. 2014 Email String re New QC measure for Edisons	03/23/2022	Erika Cheung* Dr. Mark Pandori
2567	2015-06-26 Boies Schiller & Flexner Letter to Erika Cheung	03/23/2022	Erika Cheung*
1106	Joseph Rago, The Wall Street Journal, <i>Elizabeth Holmes: The Breakthrough of Instant Diagnosis</i> , Sep. 8, 2013 (Exhibit not offered for truth of matter; admitted only to indicate state of mind of witness at the time he sought employment with Theranos and to show what information was publicly available)	03/30/2022	Dr. Mark Pandori* Daniel Edlin Patrick Mendenhall

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 3 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
1288	2013-11-30 Email String re Both QC Controls for Vitamin D didn't pass	03/30/2022	Erika Cheung*
1430	2014-01-16 Rosendorff Email to CLIA.Lab re CL QIO-00020 Quality Control Guidelines.docx (with Attachment: 2014-01-15 Theranos SOP – Quality Control Rules/Quality Control Policies)	03/30/2022	Erika Cheung* Dr. Adam Rosendorff
1522	02/10/2014 Email String re QC for TSH Failed After Re-run	03/30/2022	Dr. Mark Pandori*
1525	Feb 2014 Email String re <i>QC for TSK Failed After Re-run</i>	03/30/2022	Erika Cheung* Dr. Adam Rosendorff
1528	Feb. 2014 Email String re Both TSH QCs Failed	03/30/2022	Dr. Mark Pandori*
1570	Feb. 2014 Email String re proficiency testing for LDTs	03/30/2022	Erika Cheung* Dr. Mark Pandori
1580	Feb. 2014 Email String re proficiency testing for LDTs	03/30/2022	Erika Cheung * Dr. Mark Pandori
1595	02/27/2014 Email String re <i>Redundancy</i>	03/30/2022	Dr. Mark Pandori*
1662	Feb. 2014 Email String re Morning HDL Study Tecan Dilution Results	03/30/2022	Erika Cheung*
5767	Jan. 2014 Pandori/Balwani Email String re <i>Today</i>	03/30/2022	Dr. Mark Pandori*
5769	Apr. 2014 Email String re fT4 and TSH study results	03/30/2022	Dr. Mark Pandori*
5771	04/16/2014 Email String re Testosterone QCs Fail	03/30/2022	Dr. Mark Pandori*
7603BB	Regulation: Centers for Medicare & Medicaid Services, HHS, Section 493.931 <i>Routine Chemistry</i> [Redacted]	03/30/2022	Erika Cheung*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 4 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
9939	Theranos Standard Operating Procedure -CLIA Laboratory dated 11/26/2013	03/30/2022	Erika Cheung* Dr. Mark Pandori
20046	Mar 2014 Email String re Week 2 Vitamin D results	03/30/2022	Erika Cheung* Dr. Adam Rosendorff
20225	Feb-Mar 2014 Email String re New QC measure for Edisons	03/30/2022	Erika Cheung*
20451 (cover and p. 14 only)	2013 College of American Pathologists, 2013 Proficiency Testing Manual, ¶ Outlier Detection Technique	03/30/2022	Erika Cheung*
1513	Jan-Feb 2014 Email String re ADVIA 1	04/01/2022	Dr. Mark Pandori*
1548	Feb. 2014 Email String re Proficiency spreadsheet, and Attachment	04/01/2022	Erika Cheung* Mark Pandori
1620	Mar. 2014 Email String re Update: Week ending 3/16	04/01/2022	Dr. Mark Pandori*
5545	2014-05-08 Edlin Email re Updated PT/Audit Renewals since 3/18	04/01/2022	Dr. Mark Pandori*
5770	4/8/2014 Email String re Quick Question on disclosing information on PT testing	04/01/2022	Dr. Mark Pandori*
7440	April 2014 Email Stroing re slides pt, aap (and attachment: aa ppt th mwp v1.pptx: Proficiency Testing & Quality Assessment of Theranos Methods)	04/01/2022	Dr. Mark Pandori* Dr. Adam Rosendorff
20254	2014-01-29 Balwani/Pandori Email String re processes around samples and results	04/01/2022	Dr. Mark Pandori*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 5 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20258	2/25/2014 Email Chain re Parallel testing of VitD, TSH, PSA and FT4	04/01/2022	Dr. Mark Pandori*
20281	5/30/2014 Pandori/Rosendorf Email String re transition report.	04/01/2022	Dr. Mark Pandori*
20282	Feb. 2014 Email String re FYI (accreditation by CAP – auditors could be from competitor companies)	04/01/2022	Dr. Pandori*
20478	Oct. 2013 Email String re Welcome to Theranos	04/01/2022	Dr. Mark Pandori*
5780	Comerica Bank Statement of Account - Commercial Checking Statement of Theranos Inc. for period Aug 1-31, 2013	04/05/2022	So Han Spivey*
5797	Consolidated Financial Statements, Theranos, Inc. Years Ended December 31, 2008 and 2007, ERNST & YOUNG, June 26, 2009	04/05/2022	So Han Spivey*
5172	Financial Spreadsheet re Theranos, Inc. Cash Balance, 1/3/2011 – 6/26/2016	04/05/2022	So Han Spivey*
578	2012-04-05 Email String re 2010 Updated Post-close entries schedule – and Attachment: 2010 updated post-close entries schedule	04/05/2022	So Han Spivey*
792	2013-02-12 Yam/Holmes/Balwani Email String re Stanford (as Landlord to Theranos) – and Attachments: Financial Statement Analysis Template – Theranos 2012.xlsx and FS 2012.xlsx	04/05/2022	So Han Spivey*
1901	August 2014 Email String re Theranos – 2013 Tax Return PBC – and Attachment: TB123113.xlsx	04/05/2022	So Han Spivey*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 6 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
5206	Apr 2015 Email String re Theranos: 409A valuation analysis – March 25, 2015 valuation date – and Attachment: ARANCA, An Aranca Report – Theranos, Inc., FMV of common stock as of March 25, 2015, Apr. 6, 2015	04/05/2022	So Han Spivey*
3233	Theranos, Inc. & Subsidiary Form 8879-C – Tax Year Ending 2015 [prepared by Moss Adams, LLP]	04/05/2022	So Han Spivey*
7753	Nov. 2-3, 2016, Yam/Gellman Email String re Pharmaceutical payments for milestones – Privileged & Confidential, and Attachments: List of receipts from Pharma	04/05/2022	So Han Spivey* Daniel Edlin Shane Weber Daniel Mosley
5781	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Sep. 1-31, 2013	04/05/2022	So Han Spivey*
5783	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Dec. 1-31, 2013	04/05/2022	So Han Spivey*
5784	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Jan. 1-31, 2014	04/05/2022	So Han Spivey*
5785	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Feb. 1-28, 2014	04/05/2022	So Han Spivey*
5788	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Oct. 1-31, 2014	04/05/2022	So Han Spivey*
5789	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Nov. 1-30, 2014	04/05/2022	So Han Spivey*
5791	Comerica Bank Statement of Account – Commercial Checking Statement of Theranos Inc. for period Dec. 1-31, 2013	04/05/2022	So Han Spivey*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 7 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
5790	Wells Fargo Bank Statement – Account Summary WellsOne Account of Theranos Inc. for periods 11/7/2014 – 5/31/2016	04/05/2022	So Han Spivey*
5794	Theranos Shareholder List	04/05/2022	So Han Spivey*
5085	May 24-25, 2013, Holmes/Yam (Spivey) Email Chain re 409a – aranca valuation of company stock valuation	04/05/2022	So Han Spivey*
3283	July 30-31, 2013, Yam (Spivey)/Balwani/Holmes Email String re per our conversation with Attachment: Theranos Projections 2013-2014 v2 (formated).xlsx	04/05/2022	So Han Spivey*
13711	Aug. 2013 Holmes/Balwani/Yam (Spivey) Email Chain re 409a projection	04/05/2022	So Han Spivey*
5141	Dec. 7-8, 2014, Email String re 409A Valuation Report, with Attachment: 12/6/2013 ARANCA REPORT – Theranos, Inc., FMV of common stock as of September 30, 20213	04/05/2022	So Han Spivey*
3533	2014-02-16 Yam (Spivey) Email to Holmes re 409a prep	04/05/2022	So Han Spivey*
3527	12/21-23/2014 Holmes/Yam (Spivey) Email String re 409A	04/05/2022	So Han Spivey*
5190	12/31/2014 Yam (Spivey) Email to Holmes re 409A report, and Attachment: 12/31/2014 ARANCA REPORT – Theranos, Inc., FMV of common stock as of December 15, 2014	04/05/2022	So Han Spivey*
5209	4/13/2015 Yam (Spivey) Email to Holmes re 409A report as of 3/25/15, with Attachment: 4/6/2015 ARANCA REPORT – Theranos, Inc. FMV of common stock as of March 25, 2015	04/05/2022	So Han Spivey*
2623	06/25/2015 - 07/16/2015 Email Chain re sunil dhawan and re 409A	04/05/2022	So Han Spivey*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 8 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
4859 (conditionally admitted)	Theranos Confidential - <i>Projected Statement of Income</i> for periods ending 12/31/2014 and 12/31/2015	04/05/2022	So Han Spivey*
admitted in total		05/20/2022	
5454	07/24-25/2015 Email String re Horizon Media, and Attachment: DJ copy points.docx	04/05/2022	So Han Spivey*
5795	06/25/2015 Yam (Spivey) Email to Balwani re Please approve this wire	04/05/2022	So Han Spivey*
5796	Theranos Internal Document - Summary of Expenses by Category	04/05/2022	So Han Spivey*
20505	08/13/2009 Balwani Letter to Theranos re loan customer agreement between Theranos and Fidelity – Balwani Guarantor for \$10M	04/05/2022	So Han Spivey*
20511	04/19/2010 Email String re Loan for Theranos – Balwani now Guarantor for \$12M	04/05/2022	So Han Spivey*
20508	08/28/2009 Holmes Conditional Offer of Employment Letter to Balwani as Vice Chairman	04/05/2022	So Han Spivey*
20510	Theranos, Inc. Minutes of a Meeting of the Board of Directors – Friday, October 30, 2009	04/05/2022	So Han Spivey* Lisa Peterson
20512	Theranos, Inc. Minutes of Meeting of the Board of Directors – Tuesday, August 10, 2010	04/05/2022	So Han Spivey* Lisa Peterson
20128	Notice of Exercise - Common Stock Purchase Warrant	04/05/2022	So Han Spivey*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 9 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
20130	04/14/2010 Theranos, Inc. 2004 Stock Plan – Early Exercise	04/05/2022	So Han Spivey*
20129	08/21/2011 Theranos Inc. 2004 Stock Plan – Early Exercise	04/05/2022	So Han Spivey*
20135	12/16/2011 Theranos Inc.2004 Stock Plan – Early Exercise	04/05/2022	So Han Spivey*
20514	Theranos, Inc. Minutes of a Meeting of the Board of Directors – Tuesday, January 20, 2015	04/05/2022	So Han Spivey*
20516	Theranos, Inc. Minutes of a Meeting of the Board of Directors – January 14, 2013	04/05/2022	So Han Spivey*
20517	Theranos, Inc. Minutes of a Meeting of the Board of Directors – April 15, 2015	04/05/2022	So Han Spivey*
372	Theranos/Walgreens Master Purchase Agreement, July 20, 2010	04/05/2022	So Han Spivey* Nimesh Jhaveri
20206	Picture of Portion of Theranos Manufacturing Facility – Newark, California	04/05/2022	So Han Spivey*
20209	02/7/2012 Lease Agreement for Theranos Headquarters Space in Palo Alto with Stanford	04/05/2022	So Han Spivey*
20210	Lease Agreement for Newark Lab Facility between Theranos and BMR-Pacific Research Center - March 6, 2012	04/05/2022	So Han Spivey*
20211	Lease Agreement between Theranos and SkySong Office 3 for lab space in Arizona - 5/30/2014	04/05/2022	So Han Spivey*
20212	Jan/Feb 2015 Email String re business permit for new facility – East Pennsboro Township	04/05/2022	So Han Spivey*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 10 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20213	01/20/2015 Commercial Lease between Theranos and 1250 Associates re new facility in Camphill, PA	04/05/2022	So Han Spivey*
20214	Jan 2016 Email String re misc. leases expiration dates	04/05/2022	So Han Spivey*
4176	Theranos, Inc. and Subsidiary Consolidated Statement of Operations – Years Ended December 31, 2013, 2012, 2011 and 2010	04/05/2022	So Han Spivey*
20279	5/30/2014 Email to Dr. Rosendorff, and Attachment, Transition Report: transition_MWP_05_2014.docx	04/06/2022	Dr. Mark Pandori* Dr. Adam Rosendorff
20498	5/30/ Pandori Email to Ramamurthy and Balwani re Transition Report, and Attachment – Transition Report: MWP_05_2014.docx	04/06/2022	Dr. Mark Pandori*
20277	5/21/2014 Pandori/Rosendorff Email String re draft email to CLIA Laboratory Members	04/06/2022	Dr. Mark Pandori*
20496	5/27/2014 Ramamurthy Email to Pandori re Transition	04/06/2022	Dr. Mark Pandori*
20501	5/30/2014 Pandori/Balwani Email String re HCV small volume thoughts	04/06/2022	Dr. Mark Pandori*
20255	01/30/2014 Email String re VIP samples	04/06/2022	Dr. Mark Pandori*
20461	12/11/2013 Patel Email to Pandori re TNAA LDT validation reports, and Attachment(s) – draft validation reports	04/06/2022	Dr. Mark Pandori*
20444	12/13/2013 Pandori Email to Patel and Rosendorff re naat validation	04/06/2022	Dr. Mark Pandori*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 11 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20460	Dec 2013 Pandori/Patel Email String re b. parapertussi valid. Sugg.	04/06/2022	Dr. Mark Pandori*
20456	1/11/2014 Pandori Email to Balwani re Edisons et al.	04/06/2022	Dr. Mark Pandori*
20265	Mar 17-18, 2014, Balwani/Pandori/Young Email String re PA	04/06/2022	Dr. Mark Pandori*
20458	Feb. 2014 Email String re Wired article	04/06/2022	Dr. Mark Pandori*
20490	May 2014 Email Chain re Edisons	04/06/2022	Dr. Mark Pandori*
20521	May 2014 Email Chain re 33050 and 23321	04/06/2022	Dr. Mark Pandori*
188	Feb/Mar 2009 Email String re Follow up to our call	04/06/2022	Dr. Constance Cullen*
200	Theranos/Schering Corporation Services Agreement, 4/29/2009	04/06/2022	Dr. Constance Cullen*
201	Apr 2009 Email String re Need an invoice for Schering-Plough, and Attachment: 4/29/2009 Theranos Invoice SP09001 to Schering-Plough Research Institute and Protocol	04/06/2022	Dr. Constance Cullen*
192	3/30/2009 Meeting Reminder: Subject – Schering-Plough folks here – Draft agenda attached, and Attachment: Draft Meeting Agenda	04/06/2022	Dr. Constance Cullen*
223	6/16/2009 Frenzel/Cullen Email String re Assay Development	04/06/2022	Dr. Constance Cullen*
259	Dec 2009/Jan 2010 Email String re Validation Report, and Attachment: Theranos Multiplexed Assay Panel Validation Report – Human IL-6, Human TNF-α, Human CRP (hs)	04/06/2022	Dr. Constance Cullen*
262	Dec 2009/Jan 2010 Email String re Validation Report	04/06/2022	Dr. Constance Cullen*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 12 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
291	4/14/2010 Holmes Email to Jung re Follow Up from Walgreens, and Attachment: Excerpts from GSK Metabolic Study Report (Admitted for limited purpose of knowledge of recipient and not for truth of matter – top email only and attachments)	04/06/2022	Dr. Constance Cullen*
277	3/19/2010 Holmes Email to Shepard (cc: Balwani) re times to talk, and Attachment: multiplex panel validation report FDA (Note: Admitted for limited purpose of knowledge of recipient and not for truth of matter – top email only)	04/06/2022	Dr. Constance Cullen*
10574	Mar 2010 Holmes/Cullen Email String re Follow-up	04/06/2022	Dr. Constance Cullen*
959	Aug 2013 Email String re Demo on 8/13 – 4s and minilab	04/06/2022	Daniel Edlin*
961	Aug 12-13, 2013, Edlin/Holmes/Balwani Email String re devices in the demo room for tomorrow's meeting	04/06/2022	Daniel Edlin*
860	Jun 1, 2013 Email String re Sample running right now, and Attachment: Theranos Lab Report – Theranos Test report Technology Demonstration	04/06/2022	Daniel Edlin*
871	Jun 2013 Email String re demo next Tuesday (6/11) @ noon	04/06/2022	Daniel Edlin*
966 (email only)	2013-08-14 Young Email to C. Holmes, Edlin, E. Holmes, Balwani, Blickman re demo results 8_13_2013	04/06/2022	Daniel Edlin* Nimesh Jhaveri
957	8/13/2013 Email String re demo workflow	04/06/2022	Daniel Edlin* Nimesh Jhaveri
1014	Aug 2013 Email String re *important Demo this Thursday, 8/22** - PLEASE REPLY	04/06/2022	Daniel Edlin*
1157	9/23/2013 Email String re Demo tomorrow morning at ~10AM	04/06/2022	Daniel Edlin*

#### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 13 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
3070 (redacted patient name)	12/27/2015 Email String re Messaging for VIP guest (Note: Admitted subject to redaction of patient name)	04/06/2022	Daniel Edlin*
3965	9/4/2013 Blickman Email to Holmes et al. re .COM PDF + Jim Fox's comments, and Attachment: Screenshots of Theranos website (Note: not admitted to the truth of matter but notice as to website content and issues thereto)	04/06/2022	Daniel Edlin*
3981	Sep 5-6, 2013, Email String re Theranos website comments (Note: not admitted to the truth of matter but notice as to website content and issues thereto)	04/6/2022	Daniel Edlin*
5805	Archived Theranos Website Pages – February 8, 2014	04/13/2022	Daniel Edlin* Lisa Peterson Patrick Mendenhall Lynette Sawyer
5804	2013/09/09/ C. Holmes Email to Walgreens re new mechanical for patient brochure, and attachment – mechanical	04/13/2022	Daniel Edlin*
1090	2013-09-06 Email Chain re Readback	04/13/2022	Daniel Edlin*
5801	2014-02-18 Blickman Email to Holmes et al. re WIRED article, and Attachment – 2014-02-18 WIRED Article	04/13/2022	Daniel Edlin* Brent Bingham
1940	2014-09-16 Edlin Email to Holmes and Blickman re Contents of Confidential Investment Materials Binders	04/13/2022	Daniel Edlin*
4869	Presentation: Confidential Investment Materials for Rupert Murdoch	04/13/2022	Daniel Edlin*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 14 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
1752	May 21 - June 1, 2014, Edlin/Holmes/Blickman Email String re Roger Parloff - aggregated action items, and attachment — Theranos Multiplexed Panel Validation Report Schering Plough.pdf	04/13/2022	Daniel Edlin*
504	Dec 2011-Jan 2012 Maj. Cook/Holmes/Edlin Email String re Lab Set, and attachment – Background and Overview document re Theranos	04/13/2022	Daniel Edlin*
588	4/23-24/2012 Edgar/Holmes Email Chain re Theranos Update to Gen. Mattis	04/13/2022	Daniel Edlin*
1027	Jul/Aug 2013 Email String re THERANOS Limited Objective Experiment (LOE)	04/13/2022	Daniel Edlin*
5413	July 2014 Email Chain re Patient requesting physician call regarding lab results (not for truth of matter but only to show recipients)	04/13/2022	Daniel Edlin*
5387I	Misc. Balwani/Holmes text messages	04/13/2022	Daniel Edlin*
7239	2012-06-21 Pangarkar Email to Holmes re Cytometry assay development reports	04/13/2022	Daniel Edlin*
7747	Picture of Theranos 4S device	04/13/2022	Daniel Edlin*
20186	Diagram of Theranos Sample Processing Unit (miniLab) – Image of Theranos 4S device	04/13/2022	Daniel Edlin*
7243	7/31 – 8/1/2012 Holmes/Young/Edlin Email Chain re Minilab	04/13/2022	Daniel Edlin*
20538	p. 30 only - Depiction of device home screen – belmondo THERANOS CT <sub>3</sub> DIARY / VERSION # 2a/ MAY 22, 2013	04/13/2022	Daniel Edlin*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 15 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
20537	Video instruction of use of Theranos testing device	04/13/2022	Daniel Edlin*
20486	Apr 1-3, 2013 Balwani/Eldin/Young Email String to Eldin re DoD app	04/13/2022	Daniel Edlin*
7244	2012-08-01 Email String re Mens' health cartridge demo on 7.16 in Chicago	04/13/2022	Daniel Edlin*
20550	Jul 2013 Email String re Summary of Historical Edison numbers so we have a fixed point of reference on numbers going forward.	04/13/2022	Daniel Edlin*
966A	2013-08-14 Young Email to C. Holmes, Edlin, E. Holmes, Balwani, Blickman re demo results 8_13_2013, and attachment — Lab Report — 8/13/2013 Theranos Test Report Technology demonstration	04/13/2022	Daniel Edlin*
20536	Nov 13-14, 2013 Email Chain re WAG Specimens Tonight	04/13/2022	Daniel Edlin*
20173	2014-01-07 Balwani Email re demo Friday	04/13/2022	Daniel Edlin*
20175	Jan 2014 Fosque/Young/Edlin Email Chain re Demo Report for Review, and attachment – Theranos Lab Report Technology Demonstration – Khanna, Vivek	04/13/2022	Daniel Edlin*
20547	11/09/2012 Latto Email to Balwani et al re Theranos MAR/COMM – contact report – indicating attachments: Theranos White Board Notes.pdf, Theranos Brand Archetypes.pdf, Theranos nov7 audience insight v1.pdf, Theranos nov7 consumerworld.pdf, Theranos Contact Report Nov7.pdf	04/13/2022	Daniel Edlin*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 16 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20548	Nov 2012 Email String re Deliverables and timing, and attachment – table re list of deliverables (slide decks and brochures), completion dates and notes	04/13/2022	Daniel Edlin*
10467	Aug/Sep 2013 Email String re 3 info graphic questions for our website	04/13/2022	Daniel Edlin*
10469	8/30/2013 Edlin Email to Holmes re Analyte Decay Graph for .COM – Feedback needed tonight, and attachment – Analyte decay.ppt	04/13/2022	Daniel Edlin*
10468	Aug 2013 Email Chain re Analyte Decay Graph for .COM – Feedback needed tonight	04/13/2022	Daniel Edlin*
10558	Sep 2013 Email String re Brochure feedback	04/13/2022	Daniel Edlin*
20167	Sep 2013 Email string re Media Inquiry from G2 Intelligence	04/13/2022	Daniel Edlin*
10554	Aug 2013 Email String re Theranos Stats/Sources for Joe Rago Interview	04/13/2022	Daniel Edlin*
10462	Nov 2012 Coats Email Chain re ABA Rescue re 4th PI Meeting – new schedule date time location	04/15/2022	Daniel Edlin*
7694	Chung et al., High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial, CRITICAL CARE 2017/21:289	04/15/2022	Daniel Edlin*
13993; 13993A	May/June 2012 Email Chain re Theranos Demo Results – with Attachment A (13993A)	04/15/2022	Daniel Edlin*
13986	2012-06-21 Young Email to Edlin and Holmes re AFRICOM training	04/15/2022	Daniel Edlin*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 17 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
10446	July 2012 Givens/Edlin/Holmes Email String re SOCAFRICA update	04/15/2022	Daniel Edlin*
10457	Nov/Dec 2012 Murphy/Edlin/Holmes Email String re Approved IRB Protocol for Theranos LOE, and attachment - Protocol application for existing data and specimens	04/15/2022	Daniel Edlin*
20160	Feb. 2013 Edlin/Romero/Nelson/Balwani Email String re Theranos – Setting up network connection	04/15/2022	Daniel Edlin*
20472	Feb 2013 Email String re netowkring [sic] utility and connectivity in Aghanistan [sic]	04/15/2022	Daniel Edlin*
20161, 20162	Additional emails with R. Balwani re IT issues re Afghanistan	04/15/2022	Daniel Edlin*
10472	Feb 2013 Email Chain re ship date update	04/15/2022	Daniel Edlin*
4018	2013-10-28 Pfizer Meeting Invite re Theranos Site Visit	04/15/2022	Daniel Edlin* Shane Weber
20546	Nov. 2013 Email String re Pfizer/Theranos Discussions	04/15/2022	Daniel Edlin* Shane Weber
20544	Mar 2012 Email String re GSK MLSA proposal, indicating attachment – Theranos_MLSAdraft1-2012-03-12_YYV.docx	04/15/2022	Daniel Edlin*
20545	Apr 2012 GSK Meeting invite re MLSA and NDA	04/15/2022	Daniel Edlin*
13988	2015-07-02 Holmes Email to Employees re received FDA clearance on system and first lab developed test filed – HSV-1	04/15/2022	Daniel Edlin*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 18 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20183	2015-07-02 Email String re company meeting slides, and attachment - 2015-07-02 Presentation re Theranos HSV-1 510k Approval Company Meeting (Note: <i>Not admitted for truth of matter, but to Deft's State of Mind as to knowledge</i> )	04/15/2022	Daniel Edlin*
617	2012-06-05 Amended and Restated Theranos Master Service Agreement (Walgreens/Theranos)	04/19/2022	Nimesh Jhaveri*
966	2013-08-14 Young Email to C. Holmes, Edlin, E. Holmes, Balwani, Blickman re demo results 8_13_2013 (adding to previous exhibit 966A, pp. 7-8 – 2013-08-13 Theranos Test Report Technology Demonstration (Nimesh Jhaveri)	04/19/2022	Nimesh Jhaveri*
1113	2013-09-09 Theranos/Walgreens Press Release, Theranos Selects Walgreens as a Long-Term Partner Through Which to Offer Its New Clinical Laboratory Service	04/19/2022	Nimesh Jhaveri* Lisa Peterson Patrick Mendenhall John Bryan Tolbert Lynette Sawyer
1254	2013-11-18 Balwani Email to Rosan and Wasson re Theranos post from SingularityHub, and body re linked article: Small, Fast and Cheap, Theranos Is the Poster Child of Med Tech – and It's in Walgreens, SINGULARITYHUB.COM, http://singularityhub.com/2013/11/18/small-fast-and-cheap-theranos-is-the-post-child-of-med-tech-and-its-in-walgreens/	04/19/2022	Nimesh Jhaveri*
1387	2013-12-31 Amended and Restated Theranos Master Services Agreement (Theranos/Walgreens)	04/19/2022	Nimesh Jhaveri* Christopher Lucas
3755	Walgreens Program Charter: Diagnostic Testing	04/19/2022	Nimesh Jhaveri*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 19 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
1711	2014-03/14, 2014 05-06 Jhaveri Meeting Invite, and Haworth Email re Diagnostic Testing Executive Steering Committee Slide Deck, and attachment – Walgreens Presentation entitled Diagnostic Testing – Theranos Partnership, Executive Steering Committee Meeting, May 6, 2014	04/19/2022	Nimesh Jhaveri*
1755	2014-06-03 Haworth Email re 5/28 Walgreens-Theranos Partnership Meeting Minutes and Action Items, and attachment – Partnership Meeting Minutes 05-8-2014.docx	04/19/2022	Nimesh Jhaveri*
1884	2014-08-11 Haworth Email re REVISED 8/6 Walgreens- Theranos Partnership Meeting Minutes & Slide Deck, and attachments – Partnership Meeting Minutes 08-06-2014.pdf; Partnership Meeting Minutes 08-06-2014.docx; Theranos Walgreens Partnership Meeting August 2014 final.pptx	04/19/2022	Nimesh Jhaveri*
1896	2014-08-15 Nimesh Email to Balwani and Kozlowski re Thoughts and Goals	04/19/2022	Nimesh Jhaveri*
1909	2014-08-21 Jhaveri/Balwani Email String re Topics for Discussion	04/19/2022	Nimesh Jhaveri*
2214	2014-11-18 Haworth Email re 11/18 Walgreens/Theranos Partnership Meeting Agendy & Slide Deck	04/19/2022	Nimesh Jhaveri*
2275	2014-12-08 Jhaveri Email to Balwani re Contract and Other Topics	04/19/2022	Nimesh Jhaveri*
20531	2013-11-19 Email String re Hopkins – Please read	04/19/2022	Nimesh Jhaveri*
20532	Dec 2015-Jan 2016 Email String re Attorney/Client Privilege Hopkins – Walgreens Follow Up, and attachment JHU-Theranos Meeting Minutes.pdf re 4/27/2010 meeting	04/19/2022	Nimesh Jhaveri* Lisa Peterson

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 20 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20432	2013-11-13 Walgreens/Theranos Press Release - Theranos and Walgreens Expand Diagnostic Lab Theranos and Walgreens Expand Diagnostic Lab Testing to the Phoenix Metropolitan Area	04/19/2022	Nimesh Jhaveri* Christopher Lucas
1673	2014-04-15 Jhaveri Email re Diagnostic Testing - Live in 10 stores in Phoenix!!	04/19/2022	Nimesh Jhaveri*
1708	2014-05-06 Balwaini/Jhaveri Email String re details about vp vs fs	04/19/2022	Nimesh Jhaveri*
20234	2014-05-23/05-24 Email String re Wave 3 Site Survey Findings	04/19/2022	Nimesh Jhaveri*
1861	2014-07-10 Haworth Email re 7/10 Walgreens-Theranos Partnership Meeting Minutes & Action Items, and attachment – Partnership Meeting Minutes	04/19/2022	Nimesh Jhaveri*
20228	July 2014 Balwani/Wasson/Jhaveri Email String re couple of quick update	04/19/2022	Nimesh Jhaveri*
1891	Aug 2014 Balwani/Jhaveri Email String re store build out	04/19/2022	Nimesh Jhaveri*
3231	2013-08-31 Email String re GC Assay	04/20/2022	Dr. Adam Rosendorff*
1049	2013-08-29 Rosendorf/Holmes/Balwani Email String re Concerns about the launch	04/20/2022	Dr. Adam Rosendorff*
1491	Jan 28-29, 2014, Email String re End of Shift Log 1/28 2pm	04/20/2022	Dr. Adam Rosendorff*
1432	Jan 15-16, 2014, Rosendorf/Cheung/Sivaraman Email Chain re QC for EDISONS	04/20/2022	Dr. Adam Rosendorff*
1772	June 11-12, 2014, Email String re update and re Edison backlogs	04/20/2022	Dr. Adam Rosendorff*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 21 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
2188	Nov 3-5, 2014, Rosendorf/Holmes/Balwani Email String re Theranos tests	04/20/2022	Dr. Adam Rosendorff*
1724	2014-05-13 Rosendorff Email to Pangarkar re PT testing for Edisons	04/20/2022	Dr. Adam Rosendorff*
2099	2014/10/16 Rosendorff Email to Arington re Changes in primary methods and CMS reporting	04/20/2022	Dr. Adam Rosendorff*
4836	Oct 13-31, 2013, Email String re hCG precision	04/20/2022	Dr. Adam Rosendorff*
4145	May 29-30,2014, Balwani/Young/Holes Email String re OORL results	04/20/2022	Dr. Adam Rosendorff*
4147	2014-05-30 Rosendorff Email to CLS re hCG testing	04/20/2022	Dr. Adam Rosendorff*
4840	June 12-13, 2014, Email String re Patient results	04/20/2022	Dr. Adam Rosendorff*
4222	2014-09-29 Email String re Customer Issue - GM	04/20/2022	Dr. Adam Rosendorff*
1555	Feb 20-21, 2014, Rosendorff/Balwani/Young/Holmes Email String re HDL values	04/20/2022	Dr. Adam Rosendorff*
4116	2014-03-31 Rosendorff/Balwani/Young Email String re CO2 (Bicarbonate) issue	04/20/2022	Dr. Adam Rosendorff*
4189	Aug 25-27, 2014, Email String re Voided CO2 Results	04/20/2022	Dr. Adam Rosendorff*
1214	Nov 3-5, 2014, Email String re Advia in normandy	04/20/2022	Dr. Adam Rosendorff*
4124	Apr 16-17, 2014, Email String re Dr. Kwatra/Dr. Stamps	04/20/2022	Dr. Adam Rosendorff*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 22 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
4014	Oct 17-22, 2013, Young/Balwani/Holmes Email String re CLIA updates	04/20/2022	Dr. Adam Rosendorff*
1717	2:03 pm May 9-10, 2014, Email String re ISE Output – 5/9/2014 3:30:17 PM	04/20/2022	Dr. Adam Rosendorff*
4292	Oct 2014 Email String re Critical ISEs	04/20/2022	Dr. Adam Rosendorff*
4182	Aug 2014 Email String re bot experience	04/20/2022	Dr. Adam Rosendorff*
4181	Aug 2014 Email String re bot experience, cont'd.	04/20/2022	Dr. Adam Rosendorff*
4520	2015-09-14 Balwani/Fosque Email String, and attachments – Appendix B – MDF Comments. docx; Final log of Complaints and IRQs as of 9_11_15_MDF Updates.xlsx	04/20/2022	Dr. Adam Rosendorff* Audra Zachman
4047	Nov 26-27, 2014, Holmes Emails to Young et al. re path for walking the auditors	04/20/2022	Dr. Adam Rosendorff*
4323	Nov 2014 Rosendorff/C. Holmes Email String re Escalated Call – 111240	04/20/2022	Dr. Adam Rosendorff*
4314	Nov 2014 Email String re Escalated Call – 111240 (cont'd)	04/20/2022	Dr. Adam Rosendorff*
4330	Nov 2014 Rosendorff/Holmes Email String re Ebola	04/20/2022	Dr. Adam Rosendorff*
2228	2014-11-21 Email String re Redraw request 11-21-14	04/20/2022	Dr. Adam Rosendorff*
20304	Nov 2013 Email String re Interview- Langly Lee- Clia QA/QC Manager or Laboratory General Supervisor	04/20/2022	Dr. Adam Rosendorff*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 23 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20305	2013-11-25 Clinical Laboratory Improvement Amendments (CLIA Application for Certification), and attachment – Director's Attestation	04/20/2022	Dr. Adam Rosendorff*
7386	Centers for Medical and Medicaid Services Clinical Laboratory Improvement Amendments – Certificate of Compliance, dated 01/09/2014	04/20/2022	Dr. Adam Rosendorff* Sarah Bennett
9921	Standard Operating Procedure – CLIA Laboratory (Document Number CL PLN-14062, Revision: A) 2011/11/04 Master Validation Plan for Elisa Assays on Theranos Devices	04/22/2022	Dr. Adam Rosendorff*
1031	2013-08-24 Gangakhedkar Email to Young, Rosendorff, Holmes re Assay documents for review, and attachments: TSH Master Validation Plan for ELISA Assays on Theranos devices-08-23-13.docx; Theranos in house TPSA scfv t5D5tA5_Assay_Development_Report.doc; Theranos_TSH_Assay_Development_Report_4-4-11.doc	04/22/2022	Dr. Adam Rosendorff*
9379	Report: Total Prostate-Specific Antigen	04/22/2022	Dr. Adam Rosendorff*
1305	Dec 2013 Email String re TNAA update & validation plans	04/22/2022	Dr. Adam Rosendorff*
9004	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9007	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9013	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 24 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
9016	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9020	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9026	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9031	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9042	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9046	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9048	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9052	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9057	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9082	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9086	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 25 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
9098	LDT Validation Report for modified Siemens Assay of Chloride in Lithium Heparin Plasma, 09/26/2013	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9099	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9102	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9105	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9111	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9113	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9123	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9126	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9129	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9137	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9158	Estradiol ELISA Assay Validation Report on Edison 3.5 Theranos System, 8/29/2014	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 26 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
9162	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9166	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9167	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9196	hCG ELISA Assay Validation Report on Edison 3.5 Theranos System, 03/19/2014	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9201	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9240	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9243	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9245	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9252	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9260	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9264	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 27 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
9268	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9276	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9279	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9284	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9315	Assay Validation Report - Theranos LDT Validation Report CL RPT-14039 Rev. 1	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9319	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9323	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9326	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9341	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9352	2013-09-26 LDT Validation Report, Theranos Sodium Assay - Validation Report for Modified Siemens Assay of Sodium in Lithium Heparin Plasma (Approved Mar 2014)	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9368	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 28 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
9372	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9375	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9378	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9381	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9382	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9384	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9387	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9393	Assay Validation Report	04/22/2022	Dr. Adam Rosendorff* Dr. Sunil Dhawan
9409	VITAMIN B12 ELISA Assay Validation Report on Edison 3.5 Theranos System, 08/05/2014	04/22/2022	Dr. Adam Rosendorff*
9412	25OHVitD Total ELISA Assay Validation Report on Edison 3.x Theranos System	04/22/2022	Dr. Adam Rosendorff*
7462	Jul 2014 Email String re Physician questioning results	04/22/2022	Dr. Adam Rosendorff*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 29 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
7314	2013-08-13 Young Email to Holmes and Balwani re test launch list, referencing attachment - Launch Summary 8_18_2013.xlsx (email only)	04/22/2022	Dr. Adam Rosendorff*
7324	2013-09-07 Sivaraman/Rosendorff/Young Email String re Progress on ELISAs: TSH/TPSA/Vit D	04/22/2022	Dr. Adam Rosendorff*
13880	2013-09-11 Theranos HR Email to All Theranos Employees re Free Employee, Friends, and Family Screenings	04/22/2022	Dr. Adam Rosendorff*
20351	Theranos Flyer: Free Health Screening	04/22/2022	Dr. Adam Rosendorff*
12464	Nov 2013 Balwani/Rosendorff Email String re 300 U ave	04/22/2022	Dr. Adam Rosendorff*
20424	2013-11-20 Sivaraman Email to Rosendorff re Revised TSH and Vit D report, noting attachments – 13115-updated-25OHVitD total_Validation Report_MB_Rev1.docx, and 131118-UPDATED-TSH-Validation Report_MB_RevA1.docx	04/22/2022	Dr. Adam Rosendorff*
20423	2013-11-21 Rosendorff email to Sivaraman re Resided TSH and Vit D reports	04/22/2022	Dr. Adam Rosendorff*
20303	2013-11-11 Balwani/Rosendorff Email String re PHX	04/22/2022	Dr. Adam Rosendorff*
20570	7/10/2014 Gee Meeting Invite to Rosendorff et al. re Review and discuss Q1/Q2 Quality	04/22/2022	Dr. Adam Rosendorff*
13809	7/10/2014 Langly Gee Presentation re Quality Systems presentation Q1/Q2 2014 Review	04/22/2022	Dr. Adam Rosendorff*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 30 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
13905	2013-07-27 Chang Email to Rosendorff re Proficiency Testing Details, and attachment – 2012-11-27 Theranos Standard Operating Procedure – CLIA Laboratory – Doc QOP-0006, Proficiency Testing and Alternative Assessment Procedure	04/22/2022	Dr. Adam Rosendorff*
9940	Standard Operating Procedure CLIA Laboratory, Doc Number CL SOP-00021 Revision: A Proficiency Testing for Theranos Lab-Developed Tests	04/22/2022	Dr. Adam Rosendorff*
12846	Oct 2014 Rosendorff/Khan/C. Holmes Email String re Physician Inquiry [patient info redacted]	04/22/2022	Dr. Adam Rosendorff*
20302	2013-11-03 Theranos Standard Operating Procedure CLIA Laboratory, Document Number CL SOP-09121p, Revision: A, Potassium (K) Standard Operating Procedure for Modified Siemens Assay in Lithium Heparin Plasma	04/22/2022	Dr. Adam Rosendorff*
4037	Nov 2013 Email String re Demo Patients today @ 3:30pm	04/22/2022	Dr. Adam Rosendorff*
20317	April 2014 Email String re CTN 18546	04/22/2022	Dr. Adam Rosendorff*
20316	2014-04-07 Email String re GC results	04/22/2022	Dr. Adam Rosendorff*
13893	May 2014 Email String re ISE Studies	04/22/2022	Dr. Adam Rosendorff*
20342	June 2014 Email String re Patient results since 5/24 for potassium	04/22/2022	Dr. Adam Rosendorff*
20341	July 2014 Young/Balwani/Holmes/Rosendorff Email String re potassium status	04/22/2022	Dr. Adam Rosendorff*
20335	2014-10-07 Rockymore Email to Rosendorff et al. re Meeting Minutes - critical reporting and CTN releasing	04/22/2022	Dr. Adam Rosendorff*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 31 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20336	Rosendorff email to CLIA.Lab re CL COP-05040_CTN integrity and Critical Values Alters .docx, and attachment	04/22/2022	Dr. Adam Rosendorff*
7490	Oct 2014 Email String re Critical ISEs	04/22/2022	Dr. Adam Rosendorff*
20371	May 2014 Email string re CLIA Meeting	04/22/2022	Dr. Adam Rosendorff*
20564	June 2014 Email String re HCG for 30164	04/22/2022	Dr. Adam Rosendorff*
13888	June 2014 Rosendorff/Balwani Email String re Edison Backlogs	04/26/2022	Dr. Adam Rosendorff*
5418	May/June 2014 Email String re hCG Testing	04/26/2022	Dr. Adam Rosendorff*
13875	June 2014 Email String re hCG update	04/26/2022	Dr. Adam Rosendorff*
13876	June 2014 Email String re Status update on hCG	04/26/2022	Dr. Adam Rosendorff*
5421	2014-06-25 Gee Email to Balwani and Rosendorff re Instrument bring up	04/26/2022	Dr. Adam Rosendorff*
5422	2014-06-28 Gee Email to Balwani and Rosendorff re Instrument bring up	04/26/2022	Dr. Adam Rosendorff*
4316	Dec 2013 Young/Rosendorff Email String re Normandy lab	04/26/2022	Dr. Adam Rosendorff*
20565	June 2014 Email String re Patient #89751	04/26/2022	Dr. Adam Rosendorff*
20306	Rosendorff/Paz/Balwani Email String re CLIA inspectors	04/26/2022	Dr. Adam Rosendorff*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 32 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
1944	2014-09-18 Tubergen Email to Devos re Adobe Reader user sent you a file, and attachment – Roger Parloff, New Blood – Elizabeth Holmes Founded Her Revolutionary Blood Diagnostics Company, Theranos, When She was 19. It's Now Worth More than \$9 Billion, and Poised to Change Health Care, FORTUNE.COM, June 12, 2014 (Article not offered for truth)	04/26/2022	Lisa Peterson*
5809	2014-09-19 Tubergen Email to Holmes re Confidential Disclosure Agreement, and attachment – 2014-08-19 RDV Corp/Theranos Confidential Disclosure Agreement	04/26/2022	Lisa Peterson*
5432	Sept 2014 Holmes/Tubergen Email String re Confidential Disclosure Agreement	04/26/2022	Lisa Peterson*
2015	2014-10-03 L. Peterson Notes from Theranos Conference Call	04/26/2022	Lisa Peterson*
2073	2014-10-12 Peterson Email to Tubergen re Theranos memo, and attachment – 2014-10-03 Peterson/Lunt Interoffice Memorandum re Theranos	04/26/2022	Lisa Peterson*
4858	PowerPoint Presentation – Theranos Confidential Overview	04/26/2022	Lisa Peterson* Shane Weber
1853	Theranos Financial Document – Projected Statement of Income	04/26/2022	Lisa Peterson*
2107	Oct 2014 Tubergen/Holmes/Balwani/DeVos Email String re Thank you, and attachments – Investor Master Signature Page Series C-2.pdf; New Investor.zip; Theranos bank wire instruction.pdf	04/26/2022	Lisa Peterson*
2139	2014-10-28 Peterson/Balwani Email String re RDV investment	04/26/2022	Lisa Peterson*

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 33 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
2146	Oct 2014 Balwani/Peterson/Tubergen Email String re Theranos – status on number of things	04/26/2022	Lisa Peterson*
2166	RDV Approval Document – New Equity Investment re Theranos, Inc.	04/26/2022	Lisa Peterson*
5808	Copy of wire transfer from RDV Investment	04/26/2022	Lisa Peterson*
20433	2013-12-20 Walgreen Co. SEC From 8K	04/27/2022	Lisa Peterson*
2033	2014-10-06 Kungu/Peterson Email String re Theranos GP?	04/27/2022	Lisa Peterson*
2192	2014-11-06 Brieden Email re Theranos eFront Template, and attachment – Theranos Write-up for IC Approval (2).docx	04/27/2022	Lisa Peterson*
2120	2014-10-23 DeVos/Tubergen/Peterson Email String re Walgreens	04/27/2022	Lisa Peterson*
10588	Theranos, Inc. Series C-2 Preferred Stock Purchase Agreement	04/27/2022	Lisa Peterson*
2170	2014-10-31 Tubergen Email to Balwani re Executed Document, and attachment – Master Signature Page	04/27/2022	Lisa Peterson*
2098	Oct 2014 Peterson/Tubergen/Holmes/Balwani Email String re Thank you	04/27/2022	Lisa Peterson*
13987	2014-11-05 Mason/Peterson Email String re Signed write-ups	04/27/2022	Lisa Peterson*
2537	Nov 2014-May 2015 Balwani/Dhawan Email String re Lab Director	04/27/2022	Dr. Sunil Dhawan*
2248	2014-11-25 Marmer Email to Dhawan re Theranos – Dr. Dhawan Consulting Agreement	04/27/2022	Dr. Sunil Dhawan*

#### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 34 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
10527	Aug 2015 Gee/Dhawan Email String re Hello	04/27/2022	Dr. Sunil Dhawan*
2760	Sep 2015 Balwani/Dhawan Email String re update	04/27/2022	Dr. Sunil Dhawan*
2772	Sep 2015 Balwani/Dhawan Email String re thanks for the time	04/27/2022	Dr. Sunil Dhawan*
2791	2015-09-21 Ramamurthy Email to Dhawan re Welcome to Theranos, Dr. Dhawan!, and attachments – Theranos At Will Employment Confidential Information and Invention Assignment Agreement (PALIB2_2768193_3 d.pdf; 2015 Benefits Booklet.pdf; Dhawan Sunil – Offer Letter.pdf; Dhawan Sunil – Letter from CEO.pdf	04/27/2022	Dr. Sunil Dhawan*
4528	2015-09-22 Theranos PowerPoint Presentation: CLIA Laboratory Overview	04/27/2022	Dr. Sunil Dhawan*
2548	Oct 2015 Crow/Dhawan/Balwani re reporter seeking interview	04/27/2022	Dr. Sunil Dhawan*
2972	2015-11-09 Young Email to Dhawan re Lab QC review	04/27/2022	Dr. Sunil Dhawan*
20064	Saksena/Dhawan/Balwani Email String re Letter of Support for Suraj Saksena- Theranos	04/27/2022	Dr. Sunil Dhawan*
20067	2015-10-06 Dhawan Letter to California Department of Health re Clinical Chemist License Application of Dr. Suraj Saksena (Unique Identification No. 1009092)	04/27/2022	Dr. Sunil Dhawan*
10525	2014-11-21 SIEMENS MVP Summary ADVIA 2400 (S/N CA 1275000 100010 / Serum Barbiturate (sBRB), approved by Dr. Sawyer	04/27/2022	Dr. Sunil Dhawan* Lynette Sawyer

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 35 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20575	2014-12-02 Theranos Standard Operating Procedure CLIA Laboratory, Doc No CL SOP-06029 Revision B, Use and Maintenance of the Idaho Technology (BioFire) FilmArray® System for the Identification of Microorganisms by Multiplex PCR	04/27/2022	Dr. Sunil Dhawan* Lynette Sawyer
10526	2015-03-18 Theranos Standard Operating Procedure CLIA Laboratory, Document Number: CL SOP-17008 Revision: A, Roche LightCycler® Simplified Protocol	04/27/2022	Dr. Sunil Dhawan* Lynette Sawyer
10577	Theranos Job Description: Laboratory Supervisor/Technical Supervisor	04/27/2022	Dr. Sunil Dhawan*
9941	2014-01-01 Theranos Standard Operating Procedure CLIA Laboratory, Document Number CL SOP-00020 Revision: B, Proficiency testing for Theranos Lab-developed Tests (Immunoassays)	04/27/2022	Dr. Sunil Dhawan*
20467	2015-11-14 Theranos Test Plan, Product Development, Document Number CL PLN-14220, Revision A Verification Plan for DREW3, an Automated Hematology Analyzer	04/27/2022	Dr. Sunil Dhawan*
9369	2015-11-16 Theranos TSH ELISA Assay Report, Validation Document, Document No CL RPT-14250, Revision: 2, TSH-Elisa Assay Validation Report on Edison 3.5 Theranos System	04/27/2022	Dr. Sunil Dhawan*
9962	Theranos Quality System Manual, CLIA Laboratory, Document Number QSM 00001, Quality Systems Manual	04/27/2022	Dr. Sunil Dhawan*
2219	Nov 2014 Balwani/Dhawan Email String re Lab Director	04/27/2022	Dr. Sunil Dhawan*
1102	2013-09-07 Theranos Email to Shareholders re Theranos	04/29/2022	Patrick Mendenhall* Christopher Lucas

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 36 of 55

#### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
5814	2013-12-16 Theranos Email to Mendenhall re Theranos Stockholder Consents for your Signature by this Wednesday 12/18/13	04/29/2022	Patrick Mendenhall*
5825	2013-12-19 Balwani/Mendenhall Email String re Theranos	04/29/2022	Patrick Mendenhall*
4059	2013-12-22 Email String re Theranos	04/29/2022	Patrick Mendenhall*
4060	2015-08-27 Eisenman Email forwarding 2013-12-22 Email String re Theranos (as redacted)	04/29/2022	Patrick Mendenhall*
5824	Dec 27, 2013-Jan 10, 2014 Balwani/Mendenhall Email String re Mendenhall Family Partnership	04/29/2022	Patrick Mendenhall*
5823	Dec 27, 2013-Jan 13, 2014 Balwani Mendenhall Email String re Mendenhall Family Partnership	04/29/2022	Patrick Mendenhall*
5822	Dec 27, 2013-Jan 28, 2014 Balwani/Mendenhall Email String re Mendenhall Family Partnership	04/29/2022	Patrick Mendenhall*
5821	ADMITTED into Evidence: 2014-05-13 Mendenhall/Balwani/Holmes Email String re Theranos Update	04/29/2022	Patrick Mendenhall*
5820	ADMITTED into Evidence: 2014-05-13 Mendenhall/Balwani/Yam Email String re Theranos Update	04/29/2022	Patrick Mendenhall*
1776	Roger Parloff, New Blood – Elizabeth Holmes Founded Her Revolutionary Blood Diagnostics Company, Theranos, When She was 19. It's Now Worth More than \$9 Billion, and Poised to Change Health Care, FORTUNE.COM, June 12, 2014	04/29/2022	Patrick Mendenhall*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 37 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
5819	2014-12-03 Mendenhall/Balwani/Holmes Email String re Shareholder Questions (limitation – not offered for truth of matter asserted)	04/29/2022	Patrick Mendenhall*
20593	2014-02-24 Mendenhall Email re Mendenhall TF Partnership	04/29/2022	Patrick Mendenhall*
3940	2013-07-29 Lucas Email to Tolbert re Theranos New Board Members	04/29/2022	John Bryan Tolbert*
949	Jul/Aug 2013 Email String re Theranos, and re Black Diamond Ventures XII, LLC   Theranos Shareholder Letter	04/29/2022	John Bryan Tolbert*
4030	2013-11-08 Ibarra Email to Quintana re BDV Annual Meeting Confidential Presentation Deck   Offering, and attachment – BDV Annual Deck (11-01-13 – Final).pdf	04/29/2022	John Bryan Tolbert*
1346	Quintana Email re: IMPORTANT: BDV XII, LLC   Theranos Investor Update Call by CEO, Elizabeth Holmes   12/20/13	04/29/2022	John Bryan Tolbert*
5811	Dec 2013 Email String re Theranos Stockholder   Black Diamond Ventures' Participation in Series C-1 Stock Financing (limited to only top 3 emails, and not offered for truth of matter asserted, but only of notice to Mr. Balwani)	04/29/2022	John Bryan Tolbert*
3530	Theranos, Inc. Amended and Rested Series C-1 Preferred Stock Purchase Agreement - Initial Closing Date: July 1, 2010 (pp. 1-24, 32 only) (pp. 29, 42 admitted 5/11) (p. 25 admitted 5/13)	04/29/2022	John Bryan Tolbert* Alan Eisenman Christopher Lucas
3086	2016-01-29 Theranos/Tolbert Email String re For our shareholders	04/29/2022	John Bryan Tolbert*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 38 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
143	2008-10-11 Holmes Email to Power and Lipset re Follow up to our meeting, and attachment – Theranos Angiogenesis Study Report (not offered for the truth of the matter asserted – only to show exchange of information between Theranos and Pfizer)	05/03/2022	Shane Weber*
159	Nov 2008 Holmes, Lipset, Weber, Frenzel Email String re Follow up to our meeting (Theranos)	05/03/2022	Shane Weber*
162	Nov 2008 Email String re Final Report, and attachment – Theranos Angiogenesis Study Report and NDA	05/03/2022	Shane Weber*
167	2008-12-31 Summary report prepared by Shane Weber entitled Diagnostics review of Theranos' Thechnology and Final Recommendations	05/03/2022	Shane Weber*
174	2009-01-30 Weber Email to Power re Theranos wrap up	05/03/2022	Shane Weber*
10561	Feb 2009 Frenzel/Weber/Holmes Email String re Fertility assays	05/03/2022	Shane Weber*
15041	Aug 2009 Lester/Lipset/Holmes Email String re momentum – IL-6	05/03/2022	Shane Weber*
5831	2015-06-13 Balwani/Gee/Arington Email String re audit reports, and attachments – 2013-12-10 HHS Letter to Theranos re Standard-Level Deficiencies; HHS Form CMS-2567 Statement of Deficiencies	05/03/2022	Sarah Bennett*
5830	2015-09-22 Balwani Email to King, Hoague, Dearborn, and attachment – Theranos PowerPoint 2015-09-22 CLIA Laboratory Overview	05/03/2022	Sarah Bennett*
5450	HHS Form CMS-116 Clinical Laboratory Improvement Amendments (CLIA) - Application for Certification	05/03/2022	Sarah Bennett*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 39 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
5451	Theranos list of assays performed and name of instrument/device on which those tests were performed	05/03/2022	Sarah Bennett*
5453	2015-06-12 Theranos Clinical Lab Tests provided to HHS-CMS during inspection	05/03/2022	Sarah Bennett*
4533	2015-09-23 Theranos Letter to HHS-CMS re list of LDTs that Theranos tested on Theranos device (TSPUs) and time periods of when run	05/03/2022	Sarah Bennett* Lynette Sawyer Audra Zachman
4621	2016-01-25 HHS-CMS Letter to Theranos re Condition Level Deficiencies – Immediate Jeopardy, and attachment – HHS Form CMS-2567 Statement of Deficiencies and Plan of Correction	05/03/2022	Sarah Bennett*
7350	Oct 2013 Email Chain re Background Information and discussion regarding Theranos, and attachments –Theranos Background (3).doc; PowerPoint (Theranos Workflow) [note: attachments admitted only as to background]	05/03/2022	Sarah Bennett*
20631	Depiction of Walgreens Palo Alto entrance to Theranos Wellness Room	05/04/2022	Nimesh Jhaveri*
20229	Aug 2014 Balwani/Jhaveri/Kozlowski/Fluegel Email String re today's data	05/04/2022	Nimesh Jhaveri*
20231	Aug 2014 Balwani/Jhaveri/Kozlowski/Fluegel/Wasson Email String re today's data	05/04/2022	Nimesh Jhaveri*
20235	Aug 2014 Jhaveri/Miquelon Email String re Hello	05/04/2022	Nimesh Jhaveri*
20566	Aug-Oct 2014 Email Chain re Intro to Theranos and Elizabeth Holmes	05/04/2022	Nimesh Jhaveri*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 40 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20567	Dec 2014-Jan 2015 Green/Jhaveri/Golub Email Chain re GNE clinical Trials Follow up	05/04/2022	Nimesh Jhaveri*
20568	2015-01-30 Kozlowski Email to Blickman re Meeting with Abbott	05/04/2022	Nimesh Jhaveri*
20542	Jan-Feb 2015 Email String re Walgreens / Pfizer Whiteboard Session	05/04/2022	Nimesh Jhaveri*
2280	2014-12-09 Thies Outlook Meeting Invite re Copy: 8:00am PT-Walgreens/Theranos Meeting	05/04/2022	Nimesh Jhaveri*
20237	2014-12-15 Fluegel Email to Balwani, cc: Holmes re Follow-up	05/04/2022	Nimesh Jhaveri*
2339	2015-01-14 Haworth Email to Menchel et al re 1/14/15 Walgreens/Theranos Partnership Meeting Slide Deck & Supporting Materials, and attachments – PowerPoint, Agenda and Supporting Materials	05/04/2022	Nimesh Jhaveri*
20238	2015-01-21 Haworth Email re 1/14/15 Walgreens/Theranos Partnership Meeting Minutes & Action Items, and attachment - Meeting Minutes	05/04/2022	Nimesh Jhaveri*
2394	2015-02-17 Haworth Email re 2/17/15 Walgreens/Theranos Partnership Meeting Slide Deck, and attachment – Theranos PowerPoint	05/04/2022	Nimesh Jhaveri*
20242	Mar 2015 Email Chain re To-do's from Theranos contract discussion	05/04/2022	Nimesh Jhaveri*
2449	2015-03-30 Spitzer Email to Jhaveri re Theranos- time sensitive	05/04/2022	Nimesh Jhaveri*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 41 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20244	Apr 2015 Walgreens Email Chain re Theranos High Patient Volume	05/04/2022	Nimesh Jhaveri*
20247	Jun 2015 Email Chain re PHX Expansion List to Proceed	05/04/2022	Nimesh Jhaveri*
20233	Jun 2015 Jhaveri/Balwani Email Chain re Recap of Meeting	05/04/2022	Nimesh Jhaveri*
2859	2015-10-15 Diagnostic Testing Team Memo to Jhaveri re Health Services Development - Executive Summary – Theranos Partnership	05/04/2022	Nimesh Jhaveri*
273	2010-2012 Holmes/Rosan/Balwani Email String re Theranos Systems at Walgreens, and attachments –Theranos Systems at Walgreens – Overview.pdf; Theranos Systems at Walgreens – Partnership.pdf	05/04/2022	Nimesh Jhaveri*
20553	2010-09-09 Rosan Email to Holmes (and 9/10 Forward to Balwani/Young) Email String Email re Hopkins, and attachment - Summary of Hopkins/Walgreens/Theranos Meeting April 27, 2010	05/04/2022	Nimesh Jhaveri* Christopher Lucas
20442	Apr 2011 Haworth/Rosan/Young Email Chain re Asthma Test – Patty Haworth	05/04/2022	Nimesh Jhaveri*
20633	Standard Operating Procedure, CLIA Laboratory, No. CL SOP-00020, Revision B, <i>Proficiency testing for Theranos Lab-Developed Tests (Immunoassays)</i> , Effective Date: 01/01/2014	05/04/2022	Sarah Bennett*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 42 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
20619	2016-10-31 Bennett Email to Yamamoto re Evidence #7, and attachments – D5793 F9, D6115 CL SOP-00020 PT for Theranos LDTs_AAP.pdf; D5793 F9_AAP Data.pdf; D5793 F10_VitD Patient Results.pdf; D5801_Eval of INR Results.pdf; D5801_PT QC_Citrol3_March 2015.pdf; D5801_PT-INR Patient Results.pdf; D50805, D5821, D6098_PT-INR Final Reports.pdf	05/04/2022	Sarah Bennett*
4600	2015-12-08 Bennett/Hamilton Email String re Nice Job!	05/10/2022	Sarah Bennett*
20620	2015-06-15 Theranos Alternative Assessment Program (not admitted for truth of matter, but instead to show notice to CMS for preparation of survey report)	05/10/2022	Sarah Bennett*
4163	2014-07-22 Mosley Email to Holmes re Private Placement Memorandum	05/10/2022	Daniel Mosley*
4173	2014-08-18 Holmes Letter to Mosley re invitation to participate in equity transaction	05/10/2022	Daniel Mosley*
3387	Documents re Theranos, Realtime Cure, Inc., etc. provided to Daniel Mosley by Elizabeth Holmes	05/10/2022	Daniel Mosley* Alan Eisenman
3392	Theranos PowerPoint Presentation, <i>Infectious Disease work and Select Clinical Correlations</i> (part of materials provided to Daniel Mosley by Elizabeth Holmes)	05/10/2022	Daniel Mosley*
3844	2010-04-27 Johns Hopkins Medicine Summary of Hopkins/Walgreens/Theranos Meeting	05/10/2022	Daniel Mosley*
4202	Sep 2014 Mosley/Holmes Email String	05/10/2022	Daniel Mosley*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 43 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
4197	2014-09-02 Moley Letter to Kissinger re outline of analysis on Theranos, and attachment – Theranos Analysis	05/10/2022	Daniel Mosley*
4221	Sep 2014 Mosley/Holmes Email String	05/10/2022	Daniel Mosley*
4284	Oct 2014 Mosley/Holmes Email String re Meeting last Friday	05/10/2022	Daniel Mosley*
4286	2014-10-24 Balwani Email to Mosley/Holmes re investment docs, and attachments – 2014-02-07 Theranos, Inc. Amended and Restated Investors' Rights Agreement; 2014-02-07 Theranos, Inc. Amended and Restated Voting Agreement; Theranos, Inc. Certificate of Designation of Series C-2 Preferred Stock;	05/10/2022	Daniel Mosley*
4303	2014-10-30 Mosley Email to Holmes/Balwani re Master Signature Page, and attachments – Master Signature Page (Mosley Family Holdings LLC); Master Signature Page (Dracopoulos)	05/10/2022	Daniel Mosley*
2172	2014-10-31 Theranos/Holmes Memo to Mosley re confirmation re Series C-2 Preferred Stock	05/10/2022	Daniel Mosley*
2065	Oct 2014 C. Holmes/Balwani/Holmes Email String re BDT visitors to wag Saturday (not admitted for the truth of the matter asserted, but as to notice to the individuals in the emails)	05/10/2022	Daniel Mosley*
14118	Aug 2014 Holmes/Mosley/Edlin Email String re Blank CDA	05/10/2022	Daniel Mosley*
14119	Sep 2014 Mosley/Holmes Email String	05/10/2022	Daniel Mosley*
14124	2014-10-06 Mosley/Holmes Email String	05/11/2022	Daniel Mosley*
14135	Oct 2014 Mosley/Boies/Holmes Email string re Theranos	05/11/2022	Daniel Mosley*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 44 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
663	May 2010-Aug 2012 Eisenman/Holmes/Minnig Email String re June Quarterly update	05/11/2022	Alan Eisenman*
1334	Dec 2013 Holmes/Eisenman Email String re Theranos Stockholder Consents for your Signature by this Wednesday 12/18/13, and attachments – Theranos – Amended and Restated Certificate of Incorporation (Dual Class.pdf; Theranos – Amended and Restated Investor Rights Agreement (Dec 2013).pdf; Theranos – Amended and Restated Series C-1 Preferred Stock Purchase Agreement.pdf; Theranos – Amended and Restated Voting Agreement Series C-1 (December 20, 2013).pdf	05/11/2022	Alan Eisenman*
1371	Dec 2013 Theranos/Eisenman/Balwani Email String re Theranos Stockholder Consents for your Signature by this Wednesday 12/18/13, pp. 1-8 only	05/11/2022	Alan Eisenman*
2057	Oct 2014 Eisenman/Holmes/Balwani Email String re Negative report on Theranos from UBS	05/11/2022	Alan Eisenman*
2468	Apr 2015 Eisenman/Balwani/Holmes Email String re Theranos, and re PLEASE RESPOND!!!	05/11/2022	Alan Eisenman*
14103	May 2010 Eisenman/Holmes Email String re Updates on Theranos	05/11/2022	Alan Eisenman*
12285	Jun 2010 Eisenman/Holmes Email String re June call	05/11/2022	Alan Eisenman*
14224	2010-07-01 Eisenman Email to Holmes re no decision on sale of stock	05/11/2022	Alan Eisenman*
14225	Jul 2010 Eisenman/Balkenhol/Holmes re Catching Up	05/11/2022	Alan Eisenman*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 45 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
14226	Sep 2010 Eisenman/Holmes Email string re Larry Ellison	05/11/2022	Alan Eisenman*
12185	Feb 2011 Eisenman/Holmes/Balwani Email String re request for updates on Theranos	05/11/2022	Alan Eisenman*
12252	May 2012 Eisenman/Minnig Email String re Theranos updates	05/11/2022	Alan Eisenman*
713	Nov 2012 Eisenman/Minnig/Holmes Email String re Business Update	05/11/2022	Alan Eisenman*
1362	Dec 2013 Eisenman/Balwani Email String Theranos Stockholder Consents for your Signature by this Wednesday 12/18/13	05/11/2022	Alan Eisenman*
12999	Jan 2015 Eisenman/Balwani/Holmes Email String re Google Alert – Theranos	05/11/2022	Alan Eisenman*
13150	Aug 2015 Bois/Eisenhan Email String re Theranos follow up from our conversation today	05/11/2022	Alan Eisenman*
13191	Sep 2015 Eisenman/Thombridge/Zawrotny Email String re Theranos (not for the truth of matter asserted, but to witness's state of mind)	05/11/2022	Alan Eisenman*
3530	Theranos, Inc. Amended and Rested Series C-1 Preferred Stock Purchase Agreement - Initial Closing Date: July 1, 2010, pp. 29, 42	05/11/2022	Alan Eisenman*
20033	2015-05-05 Theranos Standard Operating Procedure, CLIA Laboratory, Hemoglobin A1C (HBA1C) Automated Pretreatment Method (A1C) IN Whole Blood on the ADVIA 1800 and 2400 Chemistry Systems, Document Number CL- SOP-09100	05/13/2022	Lynette Sawyer*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 46 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
20651	2015-05-05 Theranos Standard Operating Procedure, CLIA Laboratory, Theranos LIS Application User Guide, Document Number CL-SOP-05049	05/13/2022	Lynette Sawyer*
5095	2013-07-30 Theranos Email to Shareholders re Theranos (consumer launch)	05/13/2022	Christopher Lucas*
5132	Oct-Nov 2013 Hagen/Lucas/Holmes Email String re Meeting with Elizabeth (not offered for the truth of the matter, but only as to conversation between witness and Ms. Holmes and notice)	05/13/2022	Christopher Lucas*
5143	Dec 2013 Theranos/Lucas Email String re Theranos Stockholder Consents for your Signature by this Wednesday 12/18/13, and attachment – Theranos, Inc. Amended and Restated Certificate of Incorporation; Theranos, Inc. Amended and Restated Investors' Right Agreement; Theranos, Inc. Amended and Restated Series C-1 Preferred Stock Purchase Agreement	05/13/2022	Christopher Lucas*
5144	Dec 2013 Theranos/Lucas/Quintana/Holmes Email String re Theranos Stockholder Consents for your Signature by this Wednesday 12/18/13, and attachments – Signature Pages	05/13/2022	Christopher Lucas*
5444	Dec 2013 Lucas/Holmes Email String re BDV Investment	05/13/2022	Christopher Lucas*
5447	Dec 2013 Theranos/Lucas/Quintana/Yam Email String re Theranos Stockholder/Black Diamond Ventures' Participation in Series C-1 Stock Financing, and attachment – Master Signature Page	05/13/2022	Christopher Lucas*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 47 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
7366	2013-12-29 Quintana Email to BD Investors re *IMPORTANT UPDATE_PLEASE REIVE*BDV XII-B, LLC / Theranos Series C-1 Stock, and attachments – BDV Cover Letter re Acknowledgement (12-29-13).pdf; BDV XII-B Exhibit A to Letter re Theranos (A12-29-13).pdf; Black Diamond Ventures XII-B LLC – Operating Agreement.pdf; Black Diamond Ventures XII-B LLC -Subscription Agreement.pdf [pp. 2-69 only]	05/13/2022	Christopher Lucas*
5837	Dec 2013 Theranos/Quintana/Balwani/ Holmes Email String re Theranos Stockholder Consents for your Signature by this Wednesday 12/18/2013	05/13/2022	Christopher Lucas*
5836	Dec 2013 Holmes/Lucas/Quintana/ Theranos/Balwani Email String re Theranos Stockholder / Black Diamond Ventures' Participation in Series C-1 Stock Financing	05/13/2022	Christopher Lucas*
1770	2014-06-12 Theranos Email to Shareholders re Theranos (sharing Fortune magazine cover story)	05/13/2022	Christopher Lucas*
20698	2006-02-03 Theranos, Inc. Investors' Rights Agreement	05/13/2022	Christopher Lucas*
3530	Theranos, Inc. Amended and Rested Series C-1 Preferred Stock Purchase Agreement - Initial Closing Date: July 1, 2010, p. 25 – Master Signature Page	5/13/2022	Christopher Lucas*
12604	Apr 2014 Quintna/Lucas/Lynch Email String re BDV XII, LLC Theranos Appoints William H. Frist, M.D., to its Board of Directors	5/13/2022	Christopher Lucas*
12022	2005-12-22 Holmes Email to Lucas re Great to meet you!!!, and attachment: 12-22-2005 Theranos Redefining Healthcare.ppt (pp.1-5 and 26 only)	5/13/2022	Christopher Lucas*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 48 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
1805	ADMITTED into Evidence: Jun 2014 Zachman/Schapler Email String re theranos	05/13/2022	Audra Zachman*
5410	ADMITTED into Evidence: Quest Diagnostics Lab Report re 09/30/2014 Blood draw	05/13/2022	Audra Zachman* Brittany Gould
2044	ADMITTED into Evidence: Theranos Lab Report re 10/2/2014 Blood Draw	05/13/2022	Audra Zachman* Brittany Gould
3305	ADMITTED into Evidence: Quest Dianostics Lab Result Report re 10/6/2014 Blood Draw	05/13/2022	Audra Zachman* Brittany Gould
5411	ADMITTED into Evidence: Quest diagnostics Lab Result re 10/8/2014 Blood Draw	05/13/2022	Audra Zachman*
5184	ADMITTED into Evidence: Oct 2014 Theranos Email String re Partials list tonight	05/13/2022	Audra Zachman*
2083	ADMITTED into Evidence: 2014-10-14 Neville Email to Zachman re Checking Back	05/13/2022	Audra Zachman*
5412	ADMITTED into Evidence: 2014-10-22 C. Holmes Email to Zachman re Theranos – following up	05/13/2022	Audra Zachman*
4242	ADMITTED into Evidence: Theranos Lab Test Result for 10/4/2014 Blood Draw	05/13/2022	Audra Zachman*
20071	ADMITTED into Evidence: 2015-10-04 Riley Email re Theranos Electronic Orders and Results	05/13/2022	Audra Zachman*
20074	Jan 2021 Zachman/Scavdis Email String re Theranos	05/13/2022	Audra Zachman*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 49 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
4938	Theranos Test Results of Dr. Mehrl Ellsworth	05/18/2022	Dr. Mark Burnes* Dr. Mehrl Ellsworth Brian Grossman
4415	May/Jun 2015 Email String re Rerun and Call Back Request	05/18/2022	Dr. Mark Burnes*
5839	2015-08-12 Theranos Email to Bingham re Your Visit Code	05/18/2022	Brent Bingham*
5840	2015-08-21 Theranos Email to Bingham re Theranos Patient Visit Summary Details	05/18/2022	Brent Bingham*
2730	2015-08-28 Theranos Final Lab Results Report re Brent Bingham	05/18/2022	Brent Bingham*
2729	2015-08-28 Access Medical Laboratories Final Lab Results Report re Brent Bingham	05/18/2022	Brent Bingham*
5843	2015-12-11 Theranos Email to Bingham re Theranos Patient Visit Summary Details	05/18/2022	Brent Bingham*
5838	2015-12-15 Theranos Email to Bingham re Theranos Contact Confirmation	05/18/2022	Brent Bingham*
5483	2015-05-11 Theranos Final Lab Results Report re Erin Tompkins	05/18/2022	Erin Tompkins*
5484	2021-08-10 Contra Costa Health Services Human Immunodeficiency Virus (HIV) Antigen/Antibody Test Results (Confidential Test) re Erin Tompkins	05/18/2022	Erin Tompkins*
20683	CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL — Center for HIV/AIDS, Laboratory Testing for the Diagnosis of HIV Infection - Updated Recommendations, pp. 1, 9	05/18/2022	Erin Tompkins*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 50 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
14259	May 2015 Email String re Acc 182266; HIV results	05/18/2022	Erin Tompkins
1360	Dec 2013 James/Holmes Email String re investment in Theranos	05/18/2022	Brian Grossman*
1404	Grossman/Holmes/Balwani Email String re Due Diligence Questions	05/18/2022	Brian Grossman*
1422	Jan 10-14, 2014, Grossman/Balwani Email String	05/18/2022	Brian Grossman*
4077	Jan 10-17, 2014, Grossman/Balwani Email String, and attachment – Theranos ppt	05/18/2022	Brian Grossman*
1443	Jan 10-20, 2014, Grossman/Balwani Email String	05/18/2022	Brian Grossman*
1454	Jan 10-24, 2014, Grossman/Balwani Email String	05/18/2022	Brian Grossman*
1477	Jan 26-27, 2014, Grossman/Balwani Email String re Questions for Call on Financial Model and re Open Items for PFM Investment	05/18/2022	Brian Grossman*
5441	2014-01-29 Grossman Email to Clammer, and attachment Theranos_v12.xlsx	05/18/2022	Brian Grossman*
1482	Jan 26-28, 2014, Grossman/Balwani Email String re Open Items for PFM Investment	05/18/2022	Brian Grossman*
1505	2014-02-03 Theranos, Inc. Series C-2 Preferred Stock Purchase Agreement	05/18/2022	Brian Grossman*
1506	2014-02-04 Partner Investments, LP, PFM Healthcare Master Fund, LP and PFM Healthcare Principals Fund, LP Master Signature Page re Theranos Agreements	05/18/2022	Brian Grossman*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 51 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
5858 (redactged p. 7 only)	Question and Answer of Ramesh Balwani re ownership stake in Theranos	05/18/2022	Brian Grossman*
7353	2013-11-01 Laffort/James/Grossman Email Chain re Theranos	5/20/2022	Brian Grossman*
7358	2013-11-18 Grossman/Khanna Email Chain re Is this something we should work up on the private side	5/20/2022	Brian Grossman*
4052	2013/12/09 Grossman/Khanna Email Chain re Theranos	5/20/2022	Brian Grossman*
7376	2013-12-20 Khanna Email to Grossman re Theranos - comments on WAG call	5/20/2022	Brian Grossman*
7378	2013-12-24 Kahha/Rabodzey/Grossman Email Chain re Theranos	5/20/2022	Brian Grossman*
4063	Dec 24-25, 2013, Khanna/Grossman/Rabodzey Email Chain re Theranos	5/20/2022	Brian Grossman*
7388	2014-01-09 Gill Email to Grossman re Walgreen Company: Takeaways from Sharehold Meeting/Analyst Q&A	05/20/2022	Brian Grossman*
7387	2014-01-09 Khanna Email to Grossman, Balasuryan and Rabodzey re WAG and Theranos	05/20/2022	Brian Grossman*
7390	Jan 9-10, 2014, Grossman/Rabodzey Email Chain re meeting at Theranos	05/20/2022	Brian Grossman*
7391	Jan 2014 Rabodzey/Grossman/Khanna Email Chain re Theranos	05/20/2022	Brian Grossman*
14002	11:05 2014-01-15 Rabodzey Email to Khanna and Grossman re MDX and fda	05/20/2022	Brian Grossman*

# Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 52 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
7400	11:10 2014-01-23 Smith Email to Khanna re AR/VK: Dr. Anand Akerkar, PhD [Laboratory Developed Tests]	05/20/2022	Brian Grossman*
7399	11:15 am 2014-01-21 Robadzey Email to Grossman and Khanna re Theranos	05/20/2022	Brian Grossman*
20662	11:19am 2014-01-24 Rabodzey email to Khanna and Grossman re Theranos	05/20/2022	Brian Grossman*
7403	Obj 11:24 only page 1 – top portion only 2014-01-24 Rabodzey Email to Grossman and Khanna re Theranos	05/20/2022	Brian Grossman*
4088	11:32 2014-01-28 Grossman/Clammer Email String re Theranos	05/20/2022	Brian Grossman*
4089	11:34 2014-01-28 Rabodzey Enclosure Email to Graossman and Khanna re Theranos Technical and Regulatory Assessment	05/20/2022	Brian Grossman*
14054	2014-01-29 12:24pm Rabodzey Email to Grossman re Theranos diligence calls – Last call with an expert takeaways	05/20/2022	Brian Grossman*
14001	2014-01-26 Rabodzey Email to Grossman and Khanna re Theranos Test	05/20/2022	Brian Grossman*
14057	2014-01-28 Grossman//Balwani/Rabodzey/Khann/Balasuryan Email String Open Items for PFM Investment	05/20/2022	Brian Grossman*
14029	2014-01-29 Blickman/Grossman/Rabodzey Email String re Theranos Follow-up	05/20/2022	Brian Grossman*
14055	2014-01-29 Grossman/Rabodzey Email String re Theranos Follow-up	05/20/2022	Brian Grossman*
13720A	Theranos Spreadsheet	05/20/2022	Brian Grossman*

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 53 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	Date Admitted	Witness(es)
4093	PFM Spreadsheet	05/20/22	Brian Grossman*
14072	2014-01-26 James/Grossman Email Chain re theranos internal presentation	05/20/22	Brian Grossman*
7411	2014-01-30 Rabodzey Email to Summe re Final version of the Theranos presentation attached, and attachment: Theranos_v7.pdf	05/20/22	Brian Grossman*
20832	2018-10-04 Sutton Email to Schenk re Theranos 1 TB drive	06/09/2022	Richard Sonnier*
5915	2018-02-13 DOJ Cover Letter to Theranos, Inc. Custodian of Records re Grand Jury Subpoena (Investigation # 2016R00024), and attachment – 2018-02-13 Subpoena To Testify Before a Grand Jury to Custodian of Records, Theranos, Inc.	06/09/2022	Richard Sonnier*
5916	2018-04-20 Subpoena to Testify Before a Grand Jury to Theranos, Inc.	06/09/2022	Richard Sonnier*
5897	2018-08-28 Theranos/Wilmer Hale Email String re Call re LIS (priv/conf) – time sensitive	06/09/2022	Richard Sonnier*
5943	Oct 2018 DOJ Email String re Theranos 1 TB drive	06/09/2022	Richard Sonnier*
5917	Mar 2019 Bostic/O'Neill Email String re Theranos	06/09/2022	Richard Sonnier*
15004	Oct 2010 Gibbons/Holmes Email String re GSK	06/09/2022	
15058	2009-12-15 Holmes Email to Breuer re Follow up to our meeting, and attachment slides	06/09/2022	

### Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 54 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
20817 (pp. 1-4)	US FDA webpage - 510(k) Premarket Notification accessed 2022-05-18, and 2015-07-07 FDA Letter to Theranos re K143236 – Correction Letter to 7/2/2015 substantially equivalent letter	06/09/2022	
20826	Jul 2015 Theranos/FDA Email String re CW150009 CLIA Waiver Granted Notification, and 2015-07-15 US DHHS Letter to Theranos re CS15009 – Waiver Granted Notification, with attachment	06/09/2022	
15029	2013-10-23 Holmes email to Hojvat and Hobson re Tests run in Theranos CLIA laboratory from Samples collected in Theranos Wellness Centers	06/09/2022	
7286	Apr 2013 Young/Balwani/Holmes Email Chain re assays for FDA filing	06/09/2022	
20827	May-July 2015 Email String re Suraj Saksena: Clinical Lab Director application	06/09/2022	
20830	Excerpts from 2013-10-08 Provisional Patent Application entitled <i>Devices, Methods and Systems for Reducing Sample Volume</i>	06/09/2022	
20073A	Native Excel Spreadsheet: ECFSWCWC spreadsheets reflecting patients who received Theranos blood testing results after Aug 2015	06/09/2022	per stipulation
20788	2014-07-15 Tempe to Nunn re Theranos Financials, and attached Theranos income/expense statement	06/09/2022	per stipulation

## Case 5:18-cr-00258-EJD Document 1562 Filed 07/29/22 Page 55 of 55

### ADMITTED TRIAL EXHIBITS

Exhibit	Description	<b>Date Admitted</b>	Witness(es)
20145	Projected Statement of Income, Consolidated Balance Sheets, Theranos 409a Valuation page, Theranos Summary Capitalization page, and Aranca presentation	06/09/2022	per stipulation